[The Berlipril and Retalzem treatment of hypertension patients: the dynamics of the clinico-hemodynamic indices and of the vasodilating humoral factors].
Submitted in the paper are data on clinical, hemodynamic, and neurohumoral effects of monotherapy with an inhibitor of the angiotensin-converting enzyme berlipril (enalapril maleate) and a calcium antagonist of the benzothiazepine series retalzem (diltiazem resinate) versus their combination therapy. The combination therapy offers a number of important advantages over monotherapy with the above-named agents, consisting in apparent hypotensive action and a greater activation of endothelium-derived vasodilating and antiaggregation substances.
Koval'
S N
SN
Starchenko
T G
TG
Gorb
Iu G
IuG
Pen'kova
M Iu
MIu
Khasanova
Kh D
KhD
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004110:Diltiazem / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000627:therapeutic use*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D018377:Neurotransmitter Agents / Q000097:blood; D014664:Vasodilation / Q000187:drug effects*
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D018377:Neurotransmitter Agents; D004656:Enalapril; D004110:Diltiazem
Lechenie berliprilom i retalzemom bol'nykh gipertonicheskoĭ bolezn'iu: dinamika kliniko-gemodinamicheskikh pokazateleĭ i vazodilatiruiushchikh gumoral'nykh faktorov.